Company profile

Primelink BioTherapeitics(ShenZhen) Limited

Privately held: no public share price (Preclinical ADC biotech privately funded by Fosun Health Capital, Fosun Pharma and Vertex Ventures China. [resolved 2026-08-05 by resolve-null-is-public; source: https://pitchbook.com/profiles/company/515320-75]) · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Claudin 6 (CLDN6)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.